$695 | Single User
$1395 | Global License

Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Apr 2014 | 111 | In Stock

Introduction

Scope



With this year's meeting of the International Liver Congress (EASL) just over a week away (April 9-13), anticipation continues to build for the full publication of clinical data across a number of therapeutic indications.


The 2014 meeting may not have the seismic impact of recent conferences – 2012 being the notable standout, when data presented provided the first tangible evidence of the revolution in hepatitis C that is now well under way via the launch of Gilead Sciences' Sovaldi – but it remains an important fixture in the pharmaceutical calendar nonetheless, particularly given the rapid change to treatment landscapes.


Sovaldi may be on course to become the fastest ever new drug launch, but events in the past week demonstrate that commercial success will not be achieved without challenges along the way (see Spotlight On: The Sovaldi pricing debate – 5 key questions).


In addition to the well documented access and pricing issues, various nuances within the hepatitis C treatment paradigm continue to be explored. Furthermore, data due to be presented at EASL will further shape the credentials of next-generation therapies, which appear poised to further improve efficacy and convenience and provide a cure for hepatitis C in the vast majority of patients.


Although hepatitis is likely to be the key focus for most EASL attendees, the conference will also provide a platform for developers to present data in a range of other disease areas, such as non-alcoholic steatohepatitis (NASH). Thrust into the spotlight earlier this year via impressive Phase II results for a treatment being developed by Intercept Pharmaceuticals (not to mention an impressive share price performance; see ViewPoints: Intercept's staggering ascent provides early riposte to biotech rally doubters), NASH is now regularly cited by analysts as being "one of the few remaining large untapped markets that we could compare to the cholesterol or diabetes segments."


Puchase Reasons


Ahead of EASL 2014, FirstWord is polling US and EU-5-based gastroenterologists, hepatologists and infectious disease specialists this week to ascertain their expectations and interests. Specifically we will be asking...


  • What their main area of clinical interest at EASL is?

  • What they believe to be the most significant event in the HCV treatment space since EASL 2013

  • What their main area of focus will be in relation to new data on the treatment of HCV infection at EASL 2014

  • What clinical programme they are most looking forward to seeing data on at EASL 2014?

  • What the highest priority issue in the HCV treatment space is that will need to be resolved before EASL 2015

  • Table of Contents
    for Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    111 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...